Real-world outcomes in patients with Philadelphia chromosome-positive acute lymphoblastic leukemia or chronic myeloid leukemia treated with ponatinib – final 6-year results from a Belgian registry

Background: Ponatinib is a third-generation tyrosine kinase inhibitor (TKI) for treatment of chronic myeloid leukemia (CML) and Philadelphia chromosome-positive (Ph+) acute lymphoblastic leukemia (ALL) in patients who fail or are intolerant to a second generation TKI or who carry the T315I mutation....

Fuld beskrivelse

Bibliografiske detaljer

Principais autores:	Timothy Devos, Dries Deeren, Koen Theunissen, Dominik Selleslag, Benjamin Bailly, Violaine Havelange, Philippe Lewalle, Stef Meers, Fleur Samantha Benghiat, Alain Gadisseur, Nikki Granacher, Gaëtan Vanstraelen, Hélène Vellemans, Ann De Becker, Mia Janssen, Inge Vrelust, Marie Lejeune, Ann Van de Velde, Agnès Triffet, Michael Beck, Hinde Sebti, Dominiek Mazure
Format:	Artigo
Sprog:	Inglês
Udgivet:	Taylor & Francis Group 2025-12-01
Serier:	Hematology
Fag:	Ponatinib real-world evidence registry Philadelphia chromosome-positive acute lymphoblastic leukemia chronic myeloid leukemia
Online adgang:	https://www.tandfonline.com/doi/10.1080/16078454.2025.2534196
Tags:	Tilføj Tag Ingen Tags, Vær først til at tagge denne postø!